Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked

Joseph Treat

doi:10.6004/jnccn.2020.0034

Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	XXXI
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	18
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2020.0034
State	Published - Jul 2020

Access to Document

10.6004/jnccn.2020.0034

Fingerprint

Dive into the research topics of 'Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked'. Together they form a unique fingerprint.

Cite this

@article{c6ce45196f28498992dbfee148276f82,

title = "Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked",

author = "Joseph Treat",

year = "2020",

month = jul,

doi = "10.6004/jnccn.2020.0034",

language = "English",

volume = "18",

pages = "XXXI",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked. / Treat, Joseph.
In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 18, No. 7, 07.2020, p. XXXI.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Th-138

T2 - Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked

AU - Treat, Joseph

PY - 2020/7

Y1 - 2020/7

UR - http://www.scopus.com/inward/record.url?scp=85090758833&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0034

DO - 10.6004/jnccn.2020.0034

M3 - Comment/debate

AN - SCOPUS:85090758833

SN - 1540-1405

VL - 18

SP - XXXI

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 7

ER -

Th-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab, in patients with Stage IV nonsquamous nsclc who harbor a sensitizing EGFR mutation or have never smoked

Access to Document

Other files and links

Fingerprint

Cite this